Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

463 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug-Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA).
Fagiuoli S, Toniutto P, Coppola N, Ancona DD, Andretta M, Bartolini F, Ferrante F, Lupi A, Palcic S, Rizzi FV, Re D, Alvarez Nieto G, Hernandez C, Frigerio F, Perrone V, Degli Esposti L, Mangia A. Fagiuoli S, et al. Among authors: coppola n. Ther Clin Risk Manag. 2023 Jan 18;19:57-65. doi: 10.2147/TCRM.S394467. eCollection 2023. Ther Clin Risk Manag. 2023. PMID: 36699017 Free PMC article.
Real life experiences in HCV management in 2018.
Viganò M, Andreoni M, Perno CF, Craxì A, Aghemo A, Alberti A, Andreone P, Babudieri S, Bonora S, Brunetto MR, Bruno R, Bruno S, Calvaruso V, Caporaso N, Cartabellotta F, Ceccherini-Silberstein F, Cento V, Ciancio A, Colombatto P, Coppola N, Di Marco V, Di Perri G, Fagiuoli S, Gaeta GB, Gasbarrini A, Lampertico P, Pellicelli A, Prestileo T, Puoti M, Raimondo G, Rizzardini G, Taliani G, Zignego AL. Viganò M, et al. Among authors: coppola n. Expert Rev Anti Infect Ther. 2019 Feb;17(2):117-128. doi: 10.1080/14787210.2019.1563755. Epub 2019 Jan 15. Expert Rev Anti Infect Ther. 2019. PMID: 30582384 Free article. Review.
Drug-Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study.
Mangia A, Scaglione F, Toniutto P, Pirisi M, Coppola N, Di Perri G, Alvarez Nieto G, Calabrese S, Hernandez C, Perrone V, Degli Esposti L, Fagiuoli S. Mangia A, et al. Among authors: coppola n. Int J Environ Res Public Health. 2021 Jul 3;18(13):7144. doi: 10.3390/ijerph18137144. Int J Environ Res Public Health. 2021. PMID: 34281080 Free PMC article.
Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection.
Gentile I, Buonomo AR, Zappulo E, Minei G, Morisco F, Borrelli F, Coppola N, Borgia G. Gentile I, et al. Among authors: coppola n. Ther Clin Risk Manag. 2014 Jun 26;10:493-504. doi: 10.2147/TCRM.S66731. eCollection 2014. Ther Clin Risk Manag. 2014. PMID: 25061308 Free PMC article. Review.
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A; ABACUS study group; AIFA team. Petta S, et al. Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10. Lancet Gastroenterol Hepatol. 2017. PMID: 28497758
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.
Ascione A, De Luca M, Melazzini M, Montilla S, Trotta MP, Petta S, Puoti M, Sangiovanni V, Messina V, Bruno S, Izzi A, Villa E, Aghemo A, Zignego AL, Orlandini A, Fontanella L, Gasbarrini A, Marzioni M, Giannini EG, Craxì A; ABACUS Study Group. Ascione A, et al. Infection. 2018 Oct;46(5):607-615. doi: 10.1007/s15010-018-1157-x. Epub 2018 May 28. Infection. 2018. PMID: 29808463
Efficacy of the "first wave" Direct Acting antivirals against HCV infection: results from the Italian LINA (Liver Network Activity) cohort.
Gentile I, Buonomo AR, Coppola C, Staiano L, Amoruso DC, Saturnino MR, Maraolo AE, Portunato F, De Pascalis S, Martini S, Crispo M, Macera M, Pinchera B, Zappulo E, Scotto R, Coppola N. Gentile I, et al. Among authors: coppola n, coppola c. New Microbiol. 2019 Apr;42(2):94-100. Epub 2019 Apr 29. New Microbiol. 2019. PMID: 31034085 Free article.
Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study.
Rinaldi L, Perrella A, Guarino M, De Luca M, Piai G, Coppola N, Pafundi PC, Ciardiello F, Fasano M, Martinelli E, Valente G, Nevola R, Monari C, Miglioresi L, Guerrera B, Berretta M, Sasso FC, Morisco F, Izzi A, Adinolfi LE. Rinaldi L, et al. Among authors: coppola n. J Transl Med. 2019 Aug 28;17(1):292. doi: 10.1186/s12967-019-2033-x. J Transl Med. 2019. PMID: 31462268 Free PMC article.
463 results